KOL Views: Might Abivax’s ABX464 point the way towards a functional HIV cure?

Abivax shares soared almost 150 percent last week after the biotech reported Phase IIa data showing that its ABX464 appears to be the first therapeutic capable of reducing HIV reservoirs in patients, raising inevitable questions about whether the small molecule – an inhibitor of Rev-mediated viral gene expression – may point the way towards a functional cure for the disease.

To provide FirstWord readers with a better understanding of the relevance of the ABX464 data, we are hosting an expert call with a key opinion leader later this week.

Key topics that will be discussed during the call include, among other things… how impressive are the Phase IIa data for ABX464, how differentiated is the compound’s mechanism of action, how might targeting Rev with a small molecule prove more useful than gene therapy approaches, how optimistic are you that ABX464 could lead to a functional cure for HIV, what important questions remain and what measures/endpoints would provide definitive answers, what other programmes may play a role in the development of a functional HIV cure, and how could these agents transform the current treatment paradigm?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the search for a cure to HIV.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.